Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cortex To Pursue CX717 In Alzheimer's Under FDA Dosing Restrictions

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will not pursue an ADHD indication until further toxicological data show an increased safety margin for higher doses.

You may also be interested in...



Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study

Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.

Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study

Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.

Cortex’ Clinical Hold On CX717 Lifted By FDA

The company may resume clinical trials of the compound, which it has studied for Alzheimer's disease and attention deficit/hyperactivity disorder.

Topics

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel